This inventor holds 3 USPTO granted patents. Top assignees: Astra Aktiebolag, Astrazeneca Ab, Other. Active years: 2000-2009.
Location History:
- Sodertalje, SE (2000)
- Södertälje, SE (2002 - 2009)
Company Filing History:
1 out of 271 
1 out of 1,529 
1 out of 834,350 Years Active: 2000-2009
Title: David Noreland: Innovator in Pharmaceutical Chemistry
Introduction
David Noreland is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel crystalline forms of medications. With a total of 3 patents to his name, Noreland's work has the potential to impact the treatment of various gastrointestinal disorders.
Latest Patents
One of Noreland's latest patents involves a novel crystalline form of omeprazole. This invention relates to a specific crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, known under the generic name omeprazole. The patent outlines the use of this crystalline form for treating gastrointestinal disorders, as well as the pharmaceutical compositions containing it and the processes for its preparation.
Career Highlights
Throughout his career, David Noreland has worked with prominent companies in the pharmaceutical industry, including Astra Aktiebolag. His experience in these organizations has contributed to his expertise in drug formulation and development.
Collaborations
Noreland has collaborated with several professionals in his field, including Karin Lövqvist and Gunnel Sunden. These collaborations have likely enriched his research and development efforts.
Conclusion
David Noreland's innovative work in pharmaceutical chemistry, particularly with omeprazole, showcases his commitment to advancing medical treatments. His contributions are valuable to the ongoing development of effective therapies for gastrointestinal disorders.